Stock Detail
PHARMASSET INC
Drug Manufacturers Other
VRUS @ Yahoo Finance | VRUS Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $71.77 | $73.94 | $0.55 | 0.77% | 0.00 | $71.22 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $72.49 | $70.08 | 1.71M | 5.43B | 1.22M | -57.42 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 75.79 | 73.78 | 71.93 | 69.92 | 68.07 |
Stock Profile
Pharmasset, Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing drugs to treat viral infections. Its primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). The company has three product candidates under development, which include Clevudine, an oral, once-daily pyrimidine nucleoside analog, which is under Phase III clinical trials for the treatment of chronic HBV infection; R7128, a pro-drug of PSI-6130 in Part 3 of a Phase I clinical trial for the treatment of HCV, through a collaboration with F. Hoffmann-LaRoche, Ltd. and Hoffmann-La Roche, Inc.; and Racivir, an oral, once-daily cytidine nucleoside analog, which has completed a Phase II clinical trial for the treatment of HIV. In addition, the company engages in the development of DFC, an oral, once-daily deoxycytidine nucleoside analog, for the treatment of HIV. Pharmasset, Inc. was founded in 1998 and is headquartered in Princeton, New Jersey.